Affiliation:
1. Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez”, Mexico
2. Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico
Abstract
Cladribine is a modified deoxyadenosine that evades the action of the enzyme adenosine deaminase, which results in an immunosuppressive effect through lymphopenia, leading to an immune cells reconstitution that helps in the treatment of autoimmune diseases such as relapsing–remitting multiple sclerosis (RRMS). Since we currently have a wide range of medications to treat RRMS, it is of great interest to identify the role that cladribine plays among all options. The main objective of this narrative review is to provide useful information, with the aid of a clinical case study, which helps physicians in making decisions to treat patients with RRMS, and provide them with the best options for efficacy and safety. Due to its selective immunosuppressive effects, cladribine is indicated for the treatment of moderate to severe activity RRMS, either in escalation therapy or as induction therapy. In this article we will also analyze the characteristics of this drug to establish the scientific bases that guide the therapeutic decision making, taking into account the balance of risks and benefits for the patient.
Publisher
Grupo Anltyk S.A. de C.V.
Reference38 articles.
1. Progressive multifocal leukoencephalopathy after cladribine treatment for hairy cell leukemia;Aletti;Neurology,2011
2. Both cladribine and alemtuzumab may effect MS via B-cell depletion;Baker;Neurol Neuroimmunol neuroinflammation,2017
3. The treatment of chronic progressive multiple sclerosis with cladribine;Beutler;Proc Natl Acad Sci U S A,1996
4. Cladribine tablets’ potential role as a key example of selective immune reconstitution therapy in multiple sclerosis;Boyko;Degener Neurol Neuromuscul Dis,2018
5. Biochemical basis for the enhanced toxicity of deoxyribonucleosides toward malignant human T cell lines;Carson;Proc Natl Acad Sci,1979